^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CASP3 elevation

i
Other names: CASP3, apopain, CPP32, CPP32B, Yama, Caspase 3
Entrez ID:
Related biomarkers:
Associations
Trials
4d
Green Synthesis of Selenium Nanoparticles Utilizing Drimia indica: Insights Into Anticancer and Antimicrobial Activities. (PubMed, Microsc Res Tech)
Additionally, DI-SeNPs exhibited antimicrobial activity against various bacteria and fungi. These findings suggest that DI-SeNPs possess significant anticancer and antimicrobial properties, mediated through mechanisms involving ROS generation, cell cycle arrest, and apoptosis induction.
Journal
|
TP53 (Tumor protein P53) • CASP3 (Caspase 3)
|
CASP3 elevation
6d
Discovery of New Immunomodulatory Anticancer Thalidomide Analogs: Design, Synthesis, Biological Evaluation and In Silico Studies. (PubMed, Chem Biodivers)
Moreover, 20a was further examined through a docking study and a 200 ns molecular dynamics simulation for its complex with VEGFR-2, along with computational ADME properties. This work suggests the high significance of compounds 20a, 7a and 28, as lead compounds for development of new effective immunomodulatory antitumor drugs.
Journal • Immunomodulating
|
KDR (Kinase insert domain receptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3)
|
CASP3 elevation
|
thalidomide
16d
Design, Synthesis, and Molecular Docking of Quinazolines Bearing Caffeoyl Moiety for Targeting of PGK1/PKM2/STAT3 Signaling Pathway in the Human Breast Cancer. (PubMed, Curr Pharm Des)
The results show that compounds 2 and 3 induce apoptotic activity by blocking the PGK1- PKM2-STAT3 signaling pathway. The present investigation opens exciting possibilities for developing innovative new anticancer quinazolines bearing caffeoyl moiety.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PGK1 (Phosphoglycerate Kinase 1) • PKM (Pyruvate Kinase M1/2)
|
STAT3 expression • CASP3 elevation
25d
Chemopreventive potential of goniothalamin in diethylnitrosamine-induced hepatocellular carcinoma through the suppression of P13K/AKT signalling pathway. (PubMed, Korean J Physiol Pharmacol)
These findings revealed that GTN subdues the P13K/AKT pathway and has auspicious chemopreventive and apoptotic actions in DEN-induced HCC. Therefore, GTN would be suggested as a new medicine in natural remedies for liver cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
BCL2 expression • CASP3 elevation
28d
In vitro effects of l-kynurenine and quinolinic acid on adhesion, migration and apoptosis in B16 F10 melanoma cells. (PubMed, Biochem Biophys Res Commun)
L-kyn and Quin demonstrated promising antimetastatic effects in their ability to elevate E-cadherin expression and induce apoptosis in B16 F10 melanoma cells. However, these effects did not occur in response to vitronectin or VLA-5 integrin alterations. Furthermore, it cannot be excluded that L-kyn also induced apoptosis in RAW 264.7 cells. As such, these effects should be confirmed in additional control cell lines and substantiated with in vivo models.
Preclinical • Journal
|
CDH1 (Cadherin 1) • CASP3 (Caspase 3)
|
CDH1 expression • CASP3 elevation
2ms
Exploring the reduction in aquaporin-4 and increased expression of ciliary neurotrophic factor with the frontal-striatal gliosis induced by chronic high-fat dietary stress. (PubMed, J Neurochem)
An elevated level of CNTF appears to act as a potential regulator, leading to AQP4 downregulation in the FS areas and demyelination in the corpus callosum. This cascade of events might contribute to neural cell damage within these regions and disrupt the glymphatic flow.
Journal
|
CASP3 (Caspase 3) • AQP4 (Aquaporin 4) • GFAP (Glial Fibrillary Acidic Protein)
|
CASP3 elevation
2ms
External pressure induced the dysfunction of Sertoli cells via the Fas/FasL signaling pathway. (PubMed, Syst Biol Reprod Med)
The caspase 8 inhibitor blocked pressure-induced apoptosis and caspase 3 activation, while the cytochrome C inhibitor did not show the same effect. Our findings suggested that external pressure induces apoptosis of Sertoli cells via the Fas/FasL signaling pathway, potentially contributing to male infertility associated with cryptorchidism.
Journal
|
FASLG (Fas ligand) • CASP3 (Caspase 3) • CASP8 (Caspase 8)
|
CASP3 elevation
2ms
Methyl Gallate Suppresses Canine Mammary Gland Tumors by Inducing Apoptosis and Anti-angiogenesis. (PubMed, Anticancer Res)
MG has potential as an anticancer drug for CMTs by promoting apoptotic cell death and reducing angiogenesis, highlighting its therapeutic promise.
Journal
|
CASP3 (Caspase 3) • ANXA5 (Annexin A5)
|
CASP3 elevation
3ms
Levofloxacin reposition-based design: synthesis, biological evaluation of new levofloxacin derivatives targeting topoisomerase II beta polymerase as promising anticancer agents, molecular docking, and physicochemical characterization. (PubMed, RSC Adv)
Physicochemical characteristics of the most promising cytotoxic compounds 3c and 5 were investigated and compared to etoposide and levofloxacin as reference drugs. However, they showed high gastrointestinal absorption and could not penetrate the blood-brain barrier.
Journal
|
CASP3 (Caspase 3)
|
CASP3 elevation
|
etoposide IV
6ms
Effect of Rosmarinic Acid on Cell Proliferation, Oxidative Stress, and Apoptosis Pathways in an Animal Model of Induced Glioblastoma Multiforme. (PubMed, Arch Med Res)
These findings provide evidence that the ability of RA to reduce tumor volume could be related to factors that modulate oxidative stress (SOD and CAT enzymes), cell proliferation (p53 and p21), and apoptosis (caspase-3).
Preclinical • Journal
|
CASP3 (Caspase 3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CAT (Catalase)
|
TP53 expression • CASP3 elevation
7ms
Celecoxib and sulindac sulfide elicit anticancer effects on PIK3CA-mutated head and neck cancer cells through endoplasmic reticulum stress, reactive oxygen species, and mitochondrial dysfunction. (PubMed, Biochem Pharmacol)
Gain-of-function mutation in the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha gene (PIK3CA) is a significant factor in head and neck cancer (HNC). Salubrinal and N-acetyl-L-cysteine attenuated celecoxib-induced mitochondrial dysfunction. Collectively, our results suggest that celecoxib and SUS efficiently suppress activating PIK3CA mutation-harboring HNC progression by inducing ER and oxidative stress and mitochondrial dysfunction, leading to apoptotic cell death, further supporting NSAID treatment as a useful strategy for oncogenic PIK3CA-mutated HNC therapy.
Journal • IO biomarker
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BCL2L11 (BCL2 Like 11) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • ATF4 (Activating Transcription Factor 4) • TNFRSF10B (TNF Receptor Superfamily Member 10b) • TCF4 (Transcription Factor 4)
|
PIK3CA mutation • PIK3CA H1047R • CASP3 elevation
|
salubrinal • celecoxib oral
8ms
Pachymic acid activates TP53INP2/TRAF6/caspase-8 pathway to promote apoptosis in renal cell carcinoma cells. (PubMed, Environ Toxicol)
Molecular docking revealed interactions between PA and TP53INP2, TRAF6. In summary, PA inhibits RCC development by upregulating TP53INP2 and promoting TRAF6-induced caspase 8 ubiquitination, activating apoptotic pathways.
Journal • PARP Biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • TP53INP2 (Tumor Protein P53 Inducible Nuclear Protein 2) • TRAF6 (TNF Receptor Associated Factor 6)
|
TP53 expression • CASP3 elevation
8ms
Elucidating the anti-cancer potential of Cinnamomum tamala essential oil against non-small cell lung cancer: A multifaceted approach involving GC-MS profiling, network pharmacology, and molecular dynamics simulations. (PubMed, Heliyon)
CTEO triggered apoptosis by arresting the cell cycle, increasing ROS accumulation, causing mitochondrial depolarisation, and elevating caspase-3, caspase-8 and caspase-9 levels in A549 cells. The above study provides insights into the pharmacological mechanisms of action of Cinnamomum tamala essential oil against non-small cell lung cancer treatment, suggesting its potential as an adjuvant therapy.
Journal
|
IL6 (Interleukin 6) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • IL17A (Interleukin 17A) • MAPK3 (Mitogen-Activated Protein Kinase 3)
|
CASP3 elevation
8ms
The interlacing anticancer effect of pharmacologic ascorbate, chloroquine, and resveratrol. (PubMed, Biofactors)
It seems resveratrol-induced cytotoxicity is independent of reactive oxygen species (ROS) generation and accompanied by a significant elevation of caspase-3/7 activity, while pharmacologic ascorbate-induced cytotoxicity shows strong ROS dependence but proved to be caspase-independent. Our results are particularly important since ascorbate and resveratrol are natural compounds without significant harmful effects on normal cells, and chloroquine is a known antimalarial drug that can easily be repurposed.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • CASP3 (Caspase 3) • CASP7 (Caspase 7)
|
KRAS mutation • CASP3 elevation
|
chloroquine phosphate
9ms
Neuroprotective effects of daidzein against ifosfamide-induced neurotoxicity in male rats: role of selected inflammatory and apoptotic markers. (PubMed, J Med Life)
Conversely, pre-treatment with DZN significantly reduced serum inflammatory markers and caspase-3 levels in tissue. The findings suggest that daidzein has anti-inflammatory and anti-apoptotic properties, potentially offering protection against IFO-induced neurotoxicity in rats.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • CASP3 (Caspase 3)
|
CASP3 elevation
|
ifosfamide
11ms
Resistomycin Inhibits Wnt/β-Catenin Signaling to Induce the Apoptotic Death of Human Colorectal Cancer Cells. (PubMed, Mar Drugs)
Overall, these results support a model wherein resistomycin inhibits Wnt/β-catenin signaling within CRC cells, thereby inducing apoptotic death. Further research may be warranted to better clarify the potential utility of this compound as a candidate drug for use in the treatment of patients suffering from this form of cancer.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3) • TCF4 (Transcription Factor 4)
|
CASP3 elevation
11ms
Phytochemically analysed extract of Ageratina adenophora (Sprengel) R.M.King & H. Rob. initiates caspase 3-dependant apoptosis in colorectal cancer cell: A synergistic approach with chemotherapeutic drugs. (PubMed, J Ethnopharmacol)
The present study evaluates the effectiveness of AHL against Colorectal cancer cell lines. AHL is cytotoxic and induces apoptosis in HCT-116 cells by caspase 3 activation and increased ROS production that can be attributed to sesquiterpenoids. Thus, the plant A. adenophora has therapeutic potential for Colorectal cancer and can be further exploited for developing anticancer drug.
Journal
|
CASP3 (Caspase 3) • ANXA5 (Annexin A5)
|
CASP3 elevation
|
cisplatin • 5-fluorouracil
12ms
TNFα induces Caspase-3 activity in hematopoietic progenitor cells CD34+, CD33+, and CD41 + of myelodysplastic syndromes. (PubMed, BMC Mol Cell Biol)
rhTNFα exposure led to an elevation in caspase-3 activity in MDS progenitor cells, especially in those that had differentiated into myeloid cell CD33 + and megakaryocyte cell CD41+, as opposed to the early progenitor cells CD34+.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • CASP3 (Caspase 3) • ITGA2B (Integrin Subunit Alpha 2b)
|
CASP3 elevation
12ms
Chlorogenic acid induces apoptosis and cell-cycle arrest in colorectal cancer cells. (PubMed, Mol Biol Rep)
Considering the cytotoxicity and cell cycle arrest and induction of apoptosis in the colon cancer cell line by CGA, it can be concluded that CGA is a suitable option for the treatment of colon cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
TP53 expression • CASP3 elevation
|
chlorogenic acid
1year
Design, synthesis of novel chromene-based scaffolds targeting hepatocellular carcinoma: Cell cycle arrest, cytotoxic effect against resistant cancer cells, apoptosis induction, and c-Src inhibition. (PubMed, Drug Dev Res)
Chromens 5 and 9 showed superior cytotoxicity over staurosporine (IC  = 18.27 μM) and vinblastine (IC  = 5.20 μM)...The ability of compound 5 to induce apoptosis was supported via elevation of caspase-3, caspase-7, caspase-9 and proapoptotic Bax protein levels in addition to downregulation of the antiapoptotic Bcl2 protein. Molecular docking studies of compound 5 showed good binding interaction pattern inside c-Src kinase enzyme active site.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • CASP7 (Caspase 7) • CSK (C-Terminal Src Kinase)
|
CASP3 elevation
|
5-fluorouracil • vinblastine
1year
Osmundacetone Inhibits Angiogenesis of Infantile Hemangiomas through Inducing Caspases and Reducing VEGFR2/MMP2. (PubMed, Anticancer Agents Med Chem)
OSC demonstrated promising results in inhibiting HemECs' proliferation, inducing apoptosis, and ameliorating pathological changes in hemangiomas in mice. Moreover, it influenced the expression of crucial caspases and angiogenesis-related proteins. These findings suggest that OSC holds potential as a novel drug for clinical treatment of IH.
Journal • PARP Biomarker
|
KDR (Kinase insert domain receptor) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • FADD (Fas associated via death domain) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • MMP9 (Matrix metallopeptidase 9)
|
KDR expression • BAX expression • CASP3 elevation • MMP9 elevation
1year
Inhibition of STAT3/5 pathway by multi-kinase inhibitor IQDMA reduces tumor growth and outperforms conventional phototherapeutic treatment regime in cutaneous T cell lymphoma murine model. (ISDS 2023)
Using a murine model, we demonstrate that the multi-kinase inhibitor IQDMA significantly outperforms conventional phototherapy (PUVA) in tumor volume reduction, apoptosis induction, and downregulation of the hyperactive STAT3/5 pathway. These key findings establish IQDMA as a potent targeted therapy for CTCL and offer compelling evidence for its clinical evaluation.
Preclinical
|
CASP3 (Caspase 3)
|
CASP3 elevation
1year
Inhibitory Effect of Small Molecule Compound TIC10 on Leukemia (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
TIC10 can effectively inhibite the proliferation of leukemia cells and induce apoptosis, and have a certain intervention effect on AML induced by MLL-AF9, indicating that TIC10 as a potential candidate drug for the treatment of leukemia.
Journal
|
CASP3 (Caspase 3) • ANXA5 (Annexin A5)
|
CASP3 elevation
|
dordaviprone (ONC201)
1year
Chrysin attenuates paclitaxel-induced hepatorenal toxicity in rats by suppressing oxidative damage, inflammation, and apoptosis. (PubMed, Life Sci)
Consequently, CR exhibited the ability to reduce oxidative DNA damage, exert anti-apoptotic and anti-inflammatory properties, and mitigate the toxic effects of Pax-induced hepatorenal toxicity.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • KIM1 (Kidney injury molecule 1)
|
BCL2 expression • BAX expression • CASP3 elevation
|
paclitaxel
1year
Design, Synthesis, and Biological Evaluation of Novel 3-Cyanopyridone/Pyrazoline Hybrids as Potential Apoptotic Antiproliferative Agents Targeting EGFR/BRAF Inhibitory Pathways. (PubMed, Molecules)
Compounds 28 and 30, akin to Erlotinib, displayed promising anticancer potential...Molecular docking studies confirmed the potential of compounds 28 and 30 to act as dual EGFR/BRAF inhibitors. Furthermore, in silico ADMET prediction indicated that most synthesized 3-cyanopyridone/pyrazoline hybrids exhibit low toxicity and minimal adverse effects.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
CASP3 elevation
|
erlotinib
1year
Shikonin Causes an Apoptotic Effect on Human Kidney Cancer Cells through Ras/MAPK and PI3K/AKT Pathways. (PubMed, Molecules)
(4) Our findings indicated that shikonin causes apoptosis of renal cancer cells by activating the Ras/MAPK and PI3K/AKT pathways. These effects of shikonin on renal cancer cells may bear important potential therapeutic implications for the treatment of renal cancer.
Journal
|
MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21) • CASP3 (Caspase 3)
|
CASP3 elevation
1year
Maltol has anti-cancer effects via modulating PD-L1 signaling pathway in B16F10 cells. (PubMed, Front Pharmacol)
These findings demonstrate that maltol restricts melanoma growth through the downregulation of PD-L1 and elicits T cell-mediated anti-cancer responses, overcoming PD-L1-mediated immunotherapy resistance of cisplatin. Therefore, maltol can be considered as an effective therapeutic agent against melanoma.
Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • CASP3 (Caspase 3) • TYRP1 (Tyrosinase Related Protein 1)
|
CASP3 elevation
|
cisplatin
1year
Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies. (PubMed, Saudi Pharm J)
The antitumor in vivo effect of the combination therapy showed significant tumor inhibition compared to monotherapy. In conclusion, combination therapy could be a potential promising strategy to treat non-small cell lung carcinoma.
Preclinical • Journal • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BCL2 expression • TP53 expression • BAX expression • CASP3 elevation
|
erlotinib • Cabometyx (cabozantinib tablet)
over1year
Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer. (PubMed, Mol Pharm)
To circumvent these problems, we loaded the Bcl-2 inhibitor ABT-737 in poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) that were wrapped with phospholipid membranes derived from 4T1 murine mammary cancer cells, which mimic the growth and metastasis of human TNBC...We posit that increasing the dose of ABT CCNPs, altering the treatment schedule, or encapsulating a more potent Bcl-2 inhibitor may yield more robust effects on tumor growth and metastasis. With further development, drug-loaded biomimetic NPs may safely treat solid tumors such as TNBC that are characterized by Bcl-2 overexpression.
Journal • IO biomarker
|
CASP3 (Caspase 3)
|
BCL2 overexpression • CASP3 elevation
|
ABT-737
over1year
Interleukin-24-mediated antitumor effects against human glioblastoma via upregulation of P38 MAPK and endogenous TRAIL-induced apoptosis and LC3-II activation-dependent autophagy. (PubMed, BMC Cancer)
Our study demonstrates the antitumor effect of IL-24 on glioblastoma and may be a promising therapeutic approach for GBM cancer gene therapy.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3)
|
BIRC5 expression • CASP3 elevation
over1year
Ganetespib with Methotrexate Acts Synergistically to Impede NF-κB/p65 Signaling in Human Lung Cancer A549 Cells. (PubMed, Pharmaceuticals (Basel))
Most importantly, the GAN/MTX combinatorial regimen impeded the activation of the NF-kB/p65 signaling pathway via repression of the expression of E-cadherin and N-cadherin, which was confirmed by molecular docking studies. Collectively, these findings demonstrated the synergistic effect of the GAN/MTX combinatorial regimen in suppressing the growth of A549 cells by modulating the NF-κB/p65 signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3) • CDH2 (Cadherin 2)
|
CDH1 expression • CASP3 elevation
|
methotrexate • ganetespib (ADX-1612)
over1year
Intranasal 15d-PGJ2 inhibits the growth of rat lactotroph pituitary neuroendocrine tumors by inducing PPARγ-dependent apoptotic and autophagic cell death. (PubMed, Front Neurosci)
In conclusion, intranasal 15d-PGJ2 suppressed the growth of rat lactotroph PitNETs by inducing PPARγ-dependent apoptotic and autophagic cell death. Therefore, 15d-PGJ2 may be a potential new drug for lactotroph PitNETs.
Preclinical • Journal
|
ER (Estrogen receptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • SQSTM1 (Sequestosome 1) • CASP3 (Caspase 3) • LAMP1 (Lysosomal Associated Membrane Protein 1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • IL1B (Interleukin 1, beta) • PRL (Prolactin)
|
CASP3 elevation
over1year
Anticancer Activity of Sinapic Acid by Inducing Apoptosis in HT-29 Human Colon Cancer Cell Line. (PubMed, Can J Physiol Pharmacol)
the levels of γ-H2AX foci are significantly higher while the levels of cytochrome-C are lower in sinapic acid treated HT-29 cells. These results indicate that sinapic acid has an antiproliferative, apoptotic and genotoxic effect on colon cancer cells.
Preclinical • Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
CASP3 elevation
over1year
Anticancer activity of lycopene in HT-29 colon cancer cell line. (PubMed, Med Oncol)
The levels of γ-H2AX foci are significantly higher while the levels of cytochrome-c are lower (p < 0.05) in lycopene-treated HT-29 cells. These results indicate that lycopene has an antiproliferative apoptotic and genotoxic effect on HT-29 colon cancer cell line.
Preclinical • Retrospective data • Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
CASP3 elevation
over1year
Efficacy of vepafestinib in preclinical models of RET fusion-driven sarcoma models (AACR 2023)
Background: Vepafestinib (TAS0953/HM06, Vepa) is a 2nd generation RET-selective inhibitor that effectively penetrates the brain, and inhibits the wildtype RET kinase domain (KD) and RET KD mutants (G810, V804, Y806, L730) (presented at AACR-NCI-EROTC 2021 meeting)...Vepa was more effective than vandetanib and similar to the FDA-approved RET inhibitors, selpercatinib (Selp) and pralsetinib (Pral), in all in vitro assays... Our preclinical results suggest that vepafestinib has the potential to more effectively manage CNS metastasis compared to selpercatinib, representing a promising new therapeutic option for patients with RET-driven sarcomas. Vepafestinib is currently in a phase 1/2 trial for adult patients with advanced solid tumors harboring RET alterations (margaRET, NCT04683250).
Preclinical • PARP Biomarker
|
RET (Ret Proto-Oncogene) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • SPECC1L (Sperm Antigen With Calponin Homology And Coiled-Coil Domains 1 Like) • CASP7 (Caspase 7) • SELP (Selectin P)
|
RET fusion • RET mutation • RET rearrangement • MYC expression • CCND1 expression • STAT3 expression • RET V804* • RET expression • CASP3 elevation
|
Retevmo (selpercatinib) • Gavreto (pralsetinib) • Caprelsa (vandetanib) • vepafestinib (TAS0953/HM06)
over1year
Chrysin Encapsulated Copper Nanoparticles with Low Dose of Gamma Radiation Elicit Tumor Cell Death Through p38 MAPK/NF-κB Pathways. (PubMed, Biol Trace Elem Res)
Comparing histopathological findings of treatment groups ends that combined treatment was of higher efficacy, showing tumor tissue regression and increase in apoptotic cells. In conclusion, CuNPs with a low dose of gamma radiation showed more powerful ability for tumor suppression via promoting oxidative state, stimulating apoptosis, and inhibiting proliferation pathway through p38MAPK/NF-κB and cyclinD1.
Journal • Tumor cell
|
CCND1 (Cyclin D1) • CASP3 (Caspase 3)
|
CASP3 elevation
almost2years
Ameliorative Effects of Thunbergia erecta L. Leaves Against the Initiation of Hepatocarcinogenesis Induced by Diethylnitrosamine in the Rat Model. (PubMed, Appl Biochem Biotechnol)
Sixty rats were divided into six groups (ten each): control group, Den group, doxorubicin/Den-treated group, butanol fraction/Den-treated group, and isolated acacetin 7-O-β-glucopyranoside/Den-treated group...This was conveyed by a significant increase of IL-1 and caspase-3, elevation of MDA and reduction of GSH, and suppression of Bcl2 and elevation of Bax expression. All parameters in butanol, ethyl acetate fractions, and isolated acacetin 7-O-β-glucopyranoside (major constituents) of T. erecta L. were significantly improved to values close to those of the control group.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BAX expression • CASP3 elevation
|
doxorubicin hydrochloride
almost2years
Euphol from Tapinanthus sp. Induces Apoptosis and Affects Signaling Proteins in Glioblastoma and Prostate Cancer Cells. (PubMed, Asian Pac J Cancer Prev)
These results indicate that euphol induces cell death in glioblastoma and prostate cancer cells and regulates significantly Erk1/2 and Akt activity in glioblastoma cells.
Journal
|
CASP3 (Caspase 3) • CASP7 (Caspase 7)
|
CASP3 elevation
almost2years
Green synthesized apigenin conjugated gold nanoparticles inhibit cholangiocarcinoma cell activity and endothelial cell angiogenesis in vitro. (PubMed, Heliyon)
The api-AuNPs significantly inhibited the migration of KKU-M055 cells and suppressed the proliferation, migration, and in vitro tube formation of vascular endothelial cells. Collectively, our findings indicate the dual abilities of api-AuNPs that potentially inhibit cancer cell growth and motility as well as endothelial cell-mediated angiogenesis, which may offer a novel therapeutic avenue to treat CCA patients effectively.
Preclinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • CASP7 (Caspase 7)
|
CASP3 elevation
2years
Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trial. (PubMed, Saudi Pharm J)
All patients who achieved a complete pathological response (n = 9) exhibited an HER2-neu positive receptor at baseline. Concomitant use of pitavastatin with standard neoadjuvant chemotherapy protocols may improve neoadjuvant chemotherapy responses in patients with breast cancer.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CCND1 (Cyclin D1) • CASP3 (Caspase 3)
|
HER-2 negative • CASP3 elevation
|
pitavastatin
2years
Molecular mechanisms of bilirubin induced G1 cell cycle arrest and apoptosis in human breast cancer cell lines: involvement of the intrinsic pathway. (PubMed, Mol Biol Rep)
To discuss, bilirubin, as a naturally occurring antiproliferative molecule, mediates growth inhibition by induction of cell cycle arrest and apoptosis in MCF-7 and MDA-MB-468 breast cancer cells. It is associated with the suppression of cyclin A, D1, and Bcl-2; induction of p53, p27, and Bax together with the activation of caspase-3 and - 9.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CCNA2 (Cyclin A2) • CASP9 (Caspase 9) • AHR (Aryl hydrocarbon receptor)
|
BCL2 expression • CCND1 expression • TP53 expression • AHR expression • CASP3 elevation • CDKN1B expression
2years
Preparation and inhibitory effect of salicin dimethyl ether in Laryngeal cancer cells through the apoptosis activation. (PubMed, Acta Biochim Pol)
The underlying mechanism involves induction of apoptosis, inhibition of PI3K/Akt pathway and promotion of miR-15a expression. Therefore, salicin dimethyl ether may be used for inhibition of laryngeal cancer growth, however, in vivo studies need to be conducted to confirm the effect.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • MIR15A (MicroRNA 15a)
|
BCL2 expression • CASP3 elevation